Krystal Biotech (KRYS) has experienced a mixed performance, with a recent 1.4% daily gain but a decline of 2.4% over the past week and 4.7% over the last three months. Currently trading at $266.04, the stock shows a strong 1-year return of 60.1% despite being undervalued by approximately 15.5%, with a target price of $315. Key developments include the expansion of its pipeline in various therapeutic areas, which may enhance revenue growth and profitability. However, concerns arise over high current valuation metrics compared to industry peers and potential profitability risks due to rising R&D costs. Investors are advised to consider these factors amidst the mixed sentiment surrounding the stock.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-valuation-check-after-strong-one-year-s
